Announcement PDF ASX Announcement 5 November 2020 Lapse of Unlisted Share Options Invion Limited (ASX.IVX) wishes to advise that on 30 October 2020 the following unlisted share options have lapsed with the resignation of Craig Newton as Managing Director and CEO. Lapsed Options 27,257,615 4,088,642 4,088,642 Exercise Price $0.0300 $0.0200 $0.0106 Expiry Date 12/02/2023 30/10/2023 31/10/2024 The number of options on hand following the lapse of the above options are as follows: *ASX security code and description *Total number of +securities on issue IVXAS UNL OPT @ $0.0175 Exp 18/11/2020 IVXAT OPT @ $0.03 Exp 12/02/2023 IVXAU OPT @ $0.02 Exp 30/10/2023 IVXAV OPT @ $0.0172 Exp 31/08/2024 IVXAAA OPT @ $0.02 Exp 01/07/2024 IVXAY OPT @ $0.0177 Exp 22/10/2024 IVXAW OPT @ $0.00 Exp 31/10/2024 IVXAZ OPT @ $0.0106 Exp 31/10/2024 5,000 207,612,166 2,725,761 20,443,211 15,928,570 20,443,211 5,689,623 2,725,762 Investor enquiries Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Media enquires Brendon Lau T: 0409 341 613 E: brendon@vantagepointpartners.com.au Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by a Sub-Committee of the Board of Invion Limited. For further information please contact investor@inviongroup.com. About Photodynamic Therapy (PDT) Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes. Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com